Tratamiento perioperatorio del paciente con antiagregación o anticoagulación

Article information

El tratamiento del paciente que recibe terapias que afectan la hemostasia normal (anticoagulantes y/o antiagregantes plaquetarios) y que será sometido a un procedimiento quirúrgico, es uno de los retos que se presentan cada vez con mayor frecuencia en los servicios de cardiología. La toma de la mejor opción terapéutica en este grupo de pacientes requiere un profundo conocimiento sobre los riesgos de sangrado en caso de continuarse el tratamiento, frente a los riesgos de trombosis o embolismo en caso de suspenderlo. Por tradición, esa decisión se ha basado más en el temor al riesgo de sangrado, por lo cual en muchos casos se ha suspendido dicha terapia de manera innecesaria. En los últimos años, la aparición de la evidencia que indica que no sólo no es alto el riesgo de sangrado sino que además la continuación de estos medicamentos en muchos casos disminuye desenlaces adversos mayores, ha llevado a replantear esta conducta. En este artículo se revisará la evidencia actual existente al respecto y se suministrarán pautas que permitan la toma de una decisión adecuada.

Palabras clave:

anticoagulantes

inhibidores de agregación plaquetaria

hemorragia

trombosis

Treatment of patients receiving therapies that affect normal hemostasis (anticoagulants and / or antiplatelet aggregators) and that will undergo surgery, is one of the challenges that arise with increasing frequency in the cardiology services. Making the best therapeutic option in these patients requires a thorough understanding of the risks of bleeding in case of continuing the treatment against the risks of thrombosis or embolism in case of stopping it. By tradition, this decision has been based more on fear to the risk of bleeding, whereby in many cases this therapy has been suspended unnecessarily. In recent years, the emergence of evidence indicates that the risk of bleeding is not high and that continuation of these drugs in many cases reduce major adverse outcomes. This has led to redefine this behavior. In this article we review the current evidence available on the subject and provide guidelines that allow making a right decision.

Keywords:

anticoagulants

platelet aggregation inhibitors

hemorrhage

thrombosis

Full text is only aviable in PDF

Bibliografía

[1.]

J.D. Douketis, P.B. Berger, A.S. Dunn, A.K. Jaffer, A.C. Spyropoulos, R.C. Becker, et al.

The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th. Edition).

Chest, 133 (2008), pp. 299S-339S

http://dx.doi.org/10.1378/chest.08-0675 | Medline

[2.]

M.J. Kovacs, C. Kearon, M. Rodger, D.R. Anderson, A.G. Turpie, S.M. Bates, et al.

Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.

Circulation, 110 (2004), pp. 1658-1663

http://dx.doi.org/10.1161/01.CIR.0000142859.77578.C9 | Medline

[3.]

K. Woods, J.D. Douketis, K. Kathirgamanathan, Q. Yi, M.A. Crowther.

Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin.

J Thromb Thrombolysis, 24 (2007), pp. 93-97

http://dx.doi.org/10.1007/s11239-007-0022-z | Medline

[4.]

M.H. Eckman, J.R. Beshansky, I. Durand-Zaleski, H.J. Levine, S.G. Pauker.

Anticoagulation for noncardiac procedures in patients with prosthetic heart valves Does low risk mean high cost?.

JAMA, 263 (1990), pp. 1513-1521

Medline

[5.]

S. Savonitto, M. Caracciolo, M. Cattaneo, S. de Servi.

Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery.

Journal of Thrombosis and Haemostasis JTH, (2011),

[6.]

E.S. Brilakis, D.J. Cohen, N.S. Kleiman, M. Pencina, D. Nassif, J. Saucedo, et al.

Incidence and clinical outcome of minor surgery in the year after drug-eluting stent implantation: results from the Evaluation of Drug-Eluting Stents and Ischemic Events Registry.

Am Heart J, 161 (2011), pp. 360-366

http://dx.doi.org/10.1016/j.ahj.2010.09.028 | Medline

[7.]

A.C. To, G. Armstrong, I. Zeng, M.W. Webster.

Noncardiac surgery and bleeding after percutaneous coronary intervention.

Circulation Cardiovascular interventions, 2 (2009), pp. 213-221

http://dx.doi.org/10.1161/CIRCINTERVENTIONS.108.830158 | Medline

[8.]

S. Anwaruddin, A.T. Askari, H. Saudye, L. Batizy, P.L. Houghtaling, M. Alamoudi, et al.

Characterization of post-operative risk associated with prior drug-eluting stent use.

JACC Cardiovascular interventions, 2 (2009), pp. 542-549

http://dx.doi.org/10.1016/j.jcin.2009.03.014 | Medline

[9.]

M.J. Whitson, A.E. Dikman, C. von Althann, S. Sanyal, J.C. Desai, N.D. Bamji, et al.

Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel?.: a prospective, randomized study involving 630 biopsies.

J Clin Gastroenterol, 45 (2011), pp. 228-233

http://dx.doi.org/10.1097/MCG.0b013e3181eb5efd | Medline

[10.]

M. Singh, N. Mehta, U.K. Murthy, V. Kaul, A. Arif, N. Newman.

Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy.

Gastrointest Endosc, 71 (2010), pp. 998-1005

http://dx.doi.org/10.1016/j.gie.2009.11.022 | Medline

[11.]

L.A. Feagins, F.S. Uddin, R.E. Davila, W.V. Harford, S.J. Spechler.

The rate of postpolypectomy bleeding for patients on uninterrupted clopidogrel therapy during elective colonoscopy is acceptably low.

Dig Dis Sci, 56 (2011), pp. 2631-2638

http://dx.doi.org/10.1007/s10620-011-1682-2 | Medline

[12.]

J.J. Sung, J.Y. Lau, J.Y. Ching, J.C. Wu, Y.T. Lee, P.W. Chiu, et al.

Continuation of lowdose aspirin therapy in peptic ulcer bleeding: a randomized trial.

Ann Intern Med, 152 (2010), pp. 1-9

http://dx.doi.org/10.7326/0003-4819-152-1-201001050-00179 | Medline

[13.]

I.T. Khubchandani, M.G. Heyrosa, S.V. Thekkeurumbil.

Optimal timing of anticoagulation pre- and post-colonoscopy with polypectomy.

Techniques in coloproctology, 15 (2011), pp. 185-189

http://dx.doi.org/10.1007/s10151-010-0668-y | Medline

[14.]

C. Tompkins, C.A. Henrikson.

Optimal strategies for the management of antiplatelet and anticoagulation medications prior to cardiac device implantation.

Cardiology Journal, 18 (2011), pp. 103-109

Medline

[15.]

U.K. Wiegand, D. LeJeune, F. Boguschewski, H. Bonnemeier, F. Eberhardt, H. Schunkert, et al.

Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy.

Chest, 126 (2004), pp. 1177-1186

http://dx.doi.org/10.1378/chest.126.4.1177 | Medline

[16.]

C. Tompkins, A. Cheng, D. Dalal, J.A. Brinker, C.T. Leng, J.E. Marine, et al.

Dual antiplatelet therapy and heparin “bridging” significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.

J Am Coll Cardiol, 55 (2010), pp. 2376-2382

http://dx.doi.org/10.1016/j.jacc.2009.12.056 | Medline

[17.]

V. Chow, I. Ranasinghe, J. Lau, H. Stowe, P. Bannon, N. Hendel, et al.

Peri-procedural anticoagulation and the incidence of haematoma formation after permanent pacemaker implantation in the elderly.

Heart, Lung & Circulation, 19 (2010), pp. 706-712

http://dx.doi.org/10.1016/j.hrtlng.2015.02.005 | Medline

[18.]

S. Thal, T. Moukabary, R. Boyella, M. Shanmugasundaram, M.K. Pierce, H. Thai, et al.

The relationship between warfarin, aspirin, and clopidogrel continuation in the peri-procedural period and the incidence of hematoma formation after device implantation.

Pacing Clin Electrophysiol, 33 (2010), pp. 385-388

http://dx.doi.org/10.1111/j.1540-8159.2009.02674.x | Medline

[19.]

A. Cheng, S. Nazarian, J.A. Brinker, C. Tompkins, D.D. Spragg, C.T. Leng, et al.

Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial.

Heart rhythm: the official journal of the Heart Rhythm Society, 8 (2011), pp. 536-540

[20.]

I. Ahmed, E. Gertner, W.B. Nelson, C.M. House, R. Dahiya, C.P. Anderson, et al.

Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation.

Heart rhythm : the official Journal of the Heart Rhythm Society, 7 (2010), pp. 745-749

[21.]

O. Cano, J. Osca, M.J. Sancho-Tello, J. Olague, J.E. Castro, A. Salvador.

Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices.

Europace : European pacing, arrhythmias, and cardiac electrophysiology: Journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 13 (2011), pp. 395-401

[22.]

J. de Bono, S. Nazir, N. Ruparelia, Y. Bashir, T. Betts, K. Rajappan.

Perioperative management of anticoagulation during device implantation-the UK perspective.

Pacing Clin Electrophysiol, 33 (2010), pp. 389-393

http://dx.doi.org/10.1111/j.1540-8159.2009.02683.x | Medline

[23.]

E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, M. Levi.

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Circulation, 124 (2011), pp. 1573-1579

http://dx.doi.org/10.1161/CIRCULATIONAHA.111.029017 | Medline